| Model Number |
EVOLUTR-34-US |
| Medical Device Problem Codes |
Fluid/Blood Leak (1250); Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Code |
Aortic Valve Insufficiency/ Regurgitation (4450)
|
| Date of Event |
01/29/2026
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
It was reported that 7 years and 5 months following the implant of a transcatheter aortic valve, severe aortic valve regurgitation was identified.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that 7 years and 6 months following the valve implant, a transcatheter aortic valve (tav) in tav was performed with a 26 millimeter (mm) non-medtronic valve.
|
| |
|
Additional Manufacturer Narrative
|
|
Updated data: b2 b5 additional codes.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Updated data: b5.H6.Additional codes.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
It was reported that 7 years and 5 months following the implant of a transcatheter aortic valve, severe aortic valve regurgitation was identified.Additional information was received to report that the severe aortic regurgitation was central regurgitation, and no treatment was performed for the failed valve.
|
| |
|
Search Alerts/Recalls
|